Hydroxyurea Monitoring Guide for Sickle Cell Disease

What Is Hydroxyurea?

Hydroxyurea (also known as hydroxycarbamide) is the most important disease-modifying therapy available for sickle cell disease. Originally developed as an antineoplastic agent, hydroxyurea was approved for SCD treatment after landmark clinical trials demonstrated its ability to dramatically reduce disease complications. It remains the only widely available, affordable disease-modifying therapy for SCD in most of Africa.

Mechanism of Action

Hydroxyurea works primarily by increasing the production of fetal hemoglobin (HbF). Fetal hemoglobin interferes with the polymerization of hemoglobin S, the fundamental molecular event that causes red blood cells to sickle. By increasing HbF from a typical baseline of 5 to 10% to 15 to 30% or higher, hydroxyurea reduces the proportion of cells that sickle, decreases hemolysis, and lowers blood viscosity.

Additional beneficial effects include reduction in white blood cell count (which reduces the inflammatory component of vaso-occlusion), increased nitric oxide production (improving vascular function), increased red cell water content (improving deformability), and reduced expression of adhesion molecules on red blood cells and endothelial cells.

Who Should Receive Hydroxyurea?

Current evidence-based guidelines recommend hydroxyurea for all patients with HbSS or HbSB0 thalassemia aged 9 months and older, regardless of disease severity. This recommendation is supported by randomized controlled trials in both adults (the MSH trial) and children (the BABY HUG trial), which demonstrated significant reductions in pain crises, acute chest syndrome, hospitalizations, and blood transfusion requirements.

For patients with HbSC or HbSB+ thalassemia, the evidence base is less robust, and hydroxyurea is generally reserved for those with frequent complications. However, ongoing clinical trials in Africa are evaluating broader indications in these genotypes.

Dosing Protocols

Hydroxyurea dosing follows a structured escalation protocol:

Starting dose: 15 to 20 mg/kg/day as a single daily oral dose. In Africa, where liquid formulations may not be available, capsules are often opened and mixed with food for pediatric patients.
Dose escalation: Increase by 5 mg/kg/day every 8 weeks if blood counts remain acceptable, up to a maximum tolerated dose (MTD) of 25 to 35 mg/kg/day. The goal is to achieve the highest dose that maintains safe blood counts.
Maximum tolerated dose: Defined as the highest dose that does not cause myelosuppression. Higher doses correlate with higher HbF levels and greater clinical benefit.
Fixed-dose approach: In resource-limited settings where frequent laboratory monitoring is challenging, a fixed dose of 20 mg/kg/day has shown significant benefit with an acceptable safety profile in the REACH trial conducted in sub-Saharan Africa.

Laboratory Monitoring Parameters

Regular laboratory monitoring is essential for safe hydroxyurea therapy. The following parameters should be monitored, and Tracka's clinical data module captures and trends all of these automatically:

Complete blood count (CBC): The most critical monitoring test. Should be checked every 4 weeks during dose escalation and every 8 to 12 weeks once on a stable dose. Key components include hemoglobin, white blood cell count with differential, absolute neutrophil count (ANC), platelet count, and reticulocyte count.
Fetal hemoglobin (HbF): Measured every 3 to 6 months to assess therapeutic response. Target HbF levels of 15 to 20% or higher indicate good response.
Mean corpuscular volume (MCV): MCV increases with hydroxyurea therapy and serves as a surrogate marker for adherence. A rise in MCV of 10 fL or more from baseline is expected in adherent patients.
Reticulocyte count: A measure of bone marrow erythropoietic activity. Hydroxyurea causes a mild suppression of reticulocyte count.
Liver function tests: Measured every 6 to 12 months. While hepatotoxicity is uncommon, baseline and periodic monitoring is recommended.
Kidney function (creatinine, BUN): Monitored every 6 to 12 months. SCD-related nephropathy is common, and hydroxyurea is primarily renally excreted.

ANC Safety Thresholds

The absolute neutrophil count is the primary safety parameter guiding hydroxyurea dose adjustments:

ANC greater than 1,500/uL: Safe range. Continue current dose or proceed with dose escalation if clinically indicated.
ANC 1,000 to 1,500/uL: Caution zone. Hold dose escalation. Recheck CBC in 2 weeks. If trending down, consider dose reduction.
ANC less than 1,000/uL: Hold hydroxyurea immediately. Recheck CBC weekly until ANC recovers above 1,500/uL. Restart at a dose 5 mg/kg/day lower than the previous dose.
Other hold criteria: Hemoglobin below 5 g/dL, platelets below 80,000/uL, or reticulocyte count below 80,000/uL with hemoglobin below 8 g/dL should also trigger a dose hold.

Adherence Measurement

Adherence to hydroxyurea is a critical determinant of clinical outcomes. Tracka supports multiple adherence assessment strategies:

MCV trending: Serial MCV values are the most practical objective marker of adherence. A consistently elevated MCV suggests ongoing drug exposure.
HbF levels: Rising or maintained HbF supports adherence; declining HbF suggests interruption.
Prescription refill tracking: Digital tracking of medication refill dates provides population-level adherence data.
Self-reported adherence: Structured adherence questionnaires administered by trained field agents provide supplementary data.

Side Effects and Patient Counseling

Hydroxyurea is generally well-tolerated at therapeutic doses. The most common side effects include mild myelosuppression (managed through dose adjustment), skin hyperpigmentation (particularly nail beds), and gastrointestinal symptoms (nausea, which typically resolves). Concerns about carcinogenicity and effects on fertility have not been substantiated by decades of clinical experience, though contraception during active therapy is recommended.

Effective patient counseling is essential for long-term adherence. Patients and caregivers should understand that hydroxyurea is a preventive therapy — its benefits are seen over months, not days. They should be counseled about the importance of daily dosing, the need for regular laboratory monitoring, and circumstances that require contacting their healthcare provider.